Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin plus Ivonescimab in Perioperative Cisplatin-Ineligible MIBC
NCT06957561Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, ivonescimab in muscle-invasive bladder cancer (MIBC), sponsored by Sun Yat-sen University. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
disitamab vedotinivonescimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06957561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957561.